200,000+ products from a single source!
sales@angenechem.com
Home > Fluorides > 162011-83-8
162011-83-8 | 2(5H)-Furanone, 3-(3,4-difluorophenyl)-4-[4-(methylsulfonyl)phenyl]-
CAS No: 162011-83-8 Catalog No: AG001SMT MDL No:
Product Description
Catalog Number:
AG001SMT
Chemical Name:
2(5H)-Furanone, 3-(3,4-difluorophenyl)-4-[4-(methylsulfonyl)phenyl]-
CAS Number:
162011-83-8
Molecular Formula:
C17H12F2O4S
Molecular Weight:
350.3366
IUPAC Name:
4-(3,4-difluorophenyl)-3-(4-methylsulfonylphenyl)-2H-furan-5-one
InChI:
InChI=1S/C17H12F2O4S/c1-24(21,22)12-5-2-10(3-6-12)13-9-23-17(20)16(13)11-4-7-14(18)15(19)8-11/h2-8H,9H2,1H3
InChI Key:
INRQTVDUZFESAO-UHFFFAOYSA-N
SMILES:
O=C1OCC(=C1c1ccc(c(c1)F)F)c1ccc(cc1)S(=O)(=O)C
Properties
Complexity:
630
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
350.042g/mol
Formal Charge:
0
Heavy Atom Count:
24
Hydrogen Bond Acceptor Count:
6
Hydrogen Bond Donor Count:
0
Isotope Atom Count:
0
Molecular Weight:
350.336g/mol
Monoisotopic Mass:
350.042g/mol
Rotatable Bond Count:
3
Topological Polar Surface Area:
68.8A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
2.5
Literature
| Title | Journal |
|---|---|
| The discovery of 4-{1-[({2,5-dimethyl-4-[4-(trifluoromethyl)benzyl]-3-thienyl}carbonyl)amino]cyclopropyl}benzoic acid (MK-2894), a potent and selective prostaglandin E2 subtype 4 receptor antagonist. | Journal of medicinal chemistry 20100311 |
| MF498 [N-{[4-(5,9-Diethoxy-6-oxo-6,8-dihydro-7H-pyrrolo[3,4-g]quinolin-7-yl)-3-methylbenzyl]sulfonyl}-2-(2-methoxyphenyl)acetamide], a selective E prostanoid receptor 4 antagonist, relieves joint inflammation and pain in rodent models of rheumatoid and osteoarthritis. | The Journal of pharmacology and experimental therapeutics 20080501 |
| Cyclooxygenase-2 inhibition improves amyloid-beta-mediated suppression of memory and synaptic plasticity. | Brain : a journal of neurology 20080301 |
| MF-tricyclic inhibits growth of experimental abdominal aortic aneurysms. | The Journal of surgical research 20070801 |
| Pharmacological characterization of a selective COX-2 inhibitor MF-tricyclic, [3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone], in multiple preclinical species. | European journal of pharmacology 20070410 |
| Cyclo-oxygenase-2 inhibition attenuates the progression of nephropathy in uninephrectomized diabetic rats. | Clinical and experimental pharmacology & physiology 20070101 |
| MF tricyclic and sulindac retard tumor formation in an animal model. | International journal of cancer 20060101 |
| Cyclo-oxygenase-2 contributes to constitutive prostanoid production in rat kidney and brain. | The Biochemical journal 20051101 |
| Cyclooxygenases, thromboxane, and atherosclerosis: plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism. | Circulation 20050125 |
| Cyclooxygenase-2 inhibitor treatment improves left ventricular function and mortality in a murine model of doxorubicin-induced heart failure. | Circulation 20040323 |
| Evaluation of loxoprofen and its alcohol metabolites for potency and selectivity of inhibition of cyclooxygenase-2. | Bioorganic & medicinal chemistry letters 20040308 |
| Effects of MF-tricyclic, a selective cyclooxygenase-2 inhibitor, on atherosclerosis progression and susceptibility to cytomegalovirus replication in apolipoprotein-E knockout mice. | Journal of the American College of Cardiology 20030521 |
| Cardiovascular and renal effects of cyclooxygenase inhibition in transgenic rats harboring mouse renin-2 gene (TGR[mREN2]27). | European journal of pharmacology 20030214 |
| No effect of cyclooxygenase inhibition on plaque size in atherosclerosis-prone mice. | Scandinavian cardiovascular journal : SCJ 20021201 |
| Effects of cyclooxygenase-2 (COX-2) inhibition on plasma and renal renin in diabetes. | The Journal of laboratory and clinical medicine 20021101 |
| Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus. | Gastroenterology 20020401 |
| Synergistic interaction between highly specific cyclooxygenase-2 inhibitor, MF-tricyclic and lovastatin in murine colorectal cancer cell lines. | Oncology reports 20020101 |
| In vitro effects of cyclooxygenase inhibitors in whole blood of horses, dogs, and cats. | American journal of veterinary research 20011101 |
| Suppression of intestinal polyps in Msh2-deficient and non-Msh2-deficient multiple intestinal neoplasia mice by a specific cyclooxygenase-2 inhibitor and by a dual cyclooxygenase-1/2 inhibitor. | Cancer research 20010815 |
Related Products
Featured Products
© 2019 Angene International Limited. All rights Reserved.